在有限阶段小细胞肺癌治疗模式的现实世界分析:临床实践的影响
Siyuan Yu1, Xiaoyi Feng1, Shengjie Li2
1Department of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Thoracic cancer
|May 2, 2025
概括
同时化学放射治疗 (cCRT) 显著改善了有限阶段小细胞肺癌 (LS-SCLC) 的存活率. 早期cCRT提供了最大的益处,而表现状况和淋巴结转移是关键的预后因素.
科学领域:
- 在瘤学瘤学.
- 胸部外科手术 胸部外科手术
- 临床研究 临床研究
背景情况:
- 局限阶段小细胞肺癌 (LS-SCLC) 提出了复杂的治疗挑战.
- 现实世界的数据对于了解当前的LS-SCLC治疗模式和未满足的临床需求至关重要.
研究的目的:
- 分析LS-SCLC患者的治疗模式.
- 确定影响LS-SCLC生存的预后因素.
- 评估放射治疗时间对患者结果的影响.
主要方法:
- 在2008年5月至2023年12月期间接受治疗的203名LS-SCLC患者的回顾性分析.
- 数据收集包括临床病理特征,治疗和生存数据.
- 使用Kaplan-Meier和Cox回归分析来评估生存率和影响因素.
主要成果:
- 平均整体存活时间 (mOS) 为28.8个月. 同时化学放射治疗 (cCRT) 显示出优异的mOS (30.1个月) 与连续治疗 (27.5个月) 或没有放射治疗 (21.7个月) 相比.
- 早期cCRT表现出比晚期cCRT更好的mOS趋势 (38.3 vs. 29.5个月).
- 低绩效状态 (ECOG > 1) 和N2/N3淋巴结转移是显著的负预后因素. 与早期cCRT相比,连续放射治疗增加了死亡风险.
结论:
- 东部合作性瘤组 (ECOG) 的表现状况和淋巴结转移是LS-SCLC的关键预后指标.
- 同时化学放射治疗 (cCRT) 与LS-SCLC的预后改善有关.
- 早期cCRT提供了显著的生存优势,而晚期cCRT仍然是一个可接受的治疗选择.
更多相关视频
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019
10.5K
07:42Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
Published on: February 7, 2021
4.8K
相关概念视频
01:21Cancer Survival Analysis
291
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
291
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K